TEL AVIV, Israel – GemmaCert, a provider of dependable solutions for cannabis analysis, has released outcomes for 2020 under its international initiative that is analytical map cannabis strength worldwide and evaluate the accuracy of advertised cannabis potency based on actual results. In 2020, GemmaCert accumulated over 1.5 million potency scans in 35 countries on 6 continents.
According to the company that is israeli the global THC average in THC-dominant plants tested on GemmaCert products in regulated areas in 2020 ended up being 15.35%. For CBD in CBD principal plants, it absolutely was 8.90%. Dry flowers form the product category that is largest in the cannabis market. According to BDS Analytics, flowers comprised 45% of U.S. cannabis retail sales in 2020.
GemmaCert flower potency data for key markets included:
|Flowers||USA||Canada||The Netherlands||South Africa||Australia||Israel|
Meanwhile, A study that is recent the University of vermont and Wake Forest University discovered that many cannabis flower services and products marketed online by dispensaries over the united states of america claimed THC amounts above 15%. This follows a youthful research in Washington state which revealed that services and products with labels claiming THC degrees of 15% or more accounted for over 90% of product sales. Unsurprisingly, the cost of cannabis rises with increasing levels of THC.
The GemmaCert information confirms that real THC effectiveness amounts take typical above 15% for THC flowers that are dominant. However, the data also indicates that a meaningful share of flowers are mislabelled with THC values higher than actual:
|THC Dominant Flowers||World||USA||Canada||Netherlands||South Africa||Australia||Israel|
|% of flowers with THC < 15%||45%||30%||37%||41%||64%||37%||38%|
Therefore, consumers need to be aware that there is a reasonable chance they are overpaying for these goods. Inaccurate labelling remains a problem that is common the cannabis industry. “Cannabis organizations need certainly to do far more to make certain their labels are accurate. Otherwise, customer trust will erode, and brands will eventually lose value,” said Dr. Setton.
“GemmaCert’s solutions for cannabis testing empower organizations to undertake rigorous, prompt, affordable, and dependable in-house screening in order to constantly confirm label accuracy,” Dr. Setton added.
GemmaCert ended up being launched in 2015 in collaboration using the Hebrew University of Jerusalem. GemmaCert products are very carefully tested and hand-assembled in Israel before shipped worldwide. Devices are TÜV Rheinland certified, CE compliant, conform with European and German Pharmacopeia, and meet privacy that is necessary information protection demands. R&D is conducted during the company’s ISO 17025 laboratory that is certified to cannabis diagnostics under license by the Israel Ministry of Health. GemmaCert owns the world’s reference database that is largest of cannabis spectra sourced from world wide over time. www.gemmacert.com